PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933297
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933297
The global women's health devices market was valued at USD 60.39 billion in 2025 and is projected to grow from USD 65.89 billion in 2026 to USD 141.57 billion by 2034, registering a CAGR of 10.03% during the forecast period (2026-2034). North America dominated the market in 2025 with a 45.70% share, driven by strong healthcare expenditure, a high prevalence of female diseases, and growing demand for technologically advanced medical devices.
Rising awareness of female health issues, increased disposable incomes, and the growing prevalence of female cancers, such as breast and ovarian cancers, and other conditions like uterine fibroids are major factors driving market growth. Additionally, younger generations of women are increasingly adopting advanced health monitoring and diagnostic devices, boosting overall market expansion.
MARKET OVERVIEW
Recent developments in the women's health space have motivated companies to invest heavily in R&D and new product launches, ranging from diagnostic and monitoring devices to therapeutic equipment. For example, in December 2021, F. Hoffmann-La Roche Ltd launched the cobas PIK3CA Mutation Test for advanced or metastatic breast cancer, enhancing treatment precision and driving device adoption.
The COVID-19 pandemic temporarily hindered market growth due to limited hospital visits and disrupted supply chains. CooperSurgical Inc., for instance, reported an 11.2% revenue decline in 2020 in its fertility segment. However, by 2021, the market rebounded with 39.2% sales growth, aided by the increasing adoption of telemedicine and remote patient care solutions.
MARKET DRIVERS
Increasing Awareness of Women's Health Issues
Enhanced healthcare infrastructure, coupled with awareness campaigns by organizations like the U.S. FDA's Health of Women Program, has significantly increased women's adoption of health devices for early detection and preventive care. These initiatives have been particularly influential among younger women, leading to greater demand for diagnostic, therapeutic, and monitoring devices.
Rising Prevalence of Female Diseases
The growing prevalence of female cancers and chronic conditions such as cervical cancer, breast cancer, and uterine fibroids has escalated demand for specialized medical devices. According to WHO 2022, cervical cancer is the 4th most common cancer among women, with 604,000 new cases reported in 2020. Such trends are driving R&D initiatives and product launches, further propelling market growth.
RESTRAINING FACTORS
Limited awareness and low healthcare penetration in emerging regions restrict market growth. In countries like India and sub-Saharan Africa, cultural taboos, low diagnostic awareness, and limited access to advanced devices result in underutilization of women's health technologies, restraining overall market expansion.
SEGMENTATION
By Application
The cancers & other chronic diseases segment accounted for 34.74% of the market in 2026, due to high demand for effective diagnostic and therapeutic devices. The pregnancy & nursing care segment and reproductive health segment follow, driven by adoption of pregnancy diagnostics, breast pumps, and contraceptive devices. Pelvic and uterine healthcare devices, including urinary incontinence solutions, are also witnessing strong growth.
By End-User
Hospitals and clinics dominated the market in 2026 with a 59.42% share, due to patient influx for diagnostic and therapeutic treatments. Home healthcare is growing fastest, as patients increasingly prefer convenient at-home monitoring solutions. The "others" segment, which includes specialized clinics and telemedicine services, is growing steadily.
REGIONAL INSIGHTS
North America led the market with USD 27.60 billion in 2025, supported by strong government initiatives, technological adoption, and healthcare investments. Europe followed, with Germany and the U.K. expected to reach USD 4.48 billion and USD 2.85 billion by 2026, respectively, driven by high prevalence of female cancers and robust healthcare infrastructure.
Asia Pacific is projected to register the strongest CAGR due to increasing awareness, improved healthcare infrastructure, and approvals for advanced devices. Japan, China, and India are expected to reach USD 3.87 billion, USD 4.68 billion, and USD 2.2 billion by 2026, respectively. Emerging regions, including Latin America and the Middle East & Africa, are experiencing moderate growth due to improving healthcare access and increasing awareness.
KEY INDUSTRY PLAYERS
Prominent players include F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, CooperSurgical Inc., Hologic Inc., Coloplast A/S, and ALLERGAN (AbbVie, Inc.). These companies are strengthening their portfolios through R&D, acquisitions, and strategic partnerships. For instance, CooperSurgical acquired Cook Medical's reproductive health portfolio for USD 875 million in 2022, expanding offerings in fertility, obstetrics, and gynecology devices.
CONCLUSION
The global women's health devices market is poised for robust growth from USD 60.39 billion in 2025 to USD 141.57 billion by 2034, driven by increasing prevalence of female diseases, awareness campaigns, technological advancements, and home healthcare adoption. Despite challenges in emerging markets, strategic investments, R&D innovations, and government initiatives are expected to sustain market expansion, making the sector highly attractive for global players and new entrants alike.
Segmentation By Application, End-user, and Region
By Application * General Health & Wellness
By End-user * Hospitals & Clinics
By Region * North America (By Application, By End-user, and By Country)